PMID- 24830183
OWN - NLM
STAT- MEDLINE
DCOM- 20140605
LR  - 20140516
IS  - 0279-1072 (Print)
IS  - 0279-1072 (Linking)
VI  - 46
IP  - 1
DP  - 2014 Jan-Mar
TI  - History and future of the Multidisciplinary Association for Psychedelic Studies 
      (MAPS).
PG  - 27-36
AB  - This article describes the teenage vision of the founder of the Multidisciplinary 
      Association for Psychedelic Studies (MAPS) that humanity's future would be aided 
      by the therapeutic and spiritual potential of psychedelic substances. The article 
      traces the trajectory of MAPS from inception in 1986 to its present, noting 
      future goals with respect to research, outreach, and harm reduction. MAPS was 
      created as a non-profit psychedelic pharmaceutical company in response to the 
      1985 scheduling of 3,4-methylenedioxymethamphetamine (MDMA). Overcoming many 
      hurdles, MAPS developed the first double-blind, placebo-controlled trial of 
      MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) and plans 
      for FDA prescription approval in 2021. MAPS' program of research expanded to 
      include a trial of lysergic acid diethylamide (LSD)-assisted psychotherapy for 
      anxiety when facing life-threatening illness, observational studies of ibogaine 
      in the treatment of addiction, and studies of MDMA for social anxiety in people 
      with autism spectrum disorders. MAPS meets the challenges of drug development 
      through a clinical research team led by a former Novartis drug development 
      professional experienced in the conduct, monitoring, and analysis of clinical 
      trials. MAPS' harm-reduction efforts are intended to avoid backlash and build a 
      post-prohibition world by assisting non-medical users to transform difficult 
      psychedelic experiences into opportunities for growth.
FAU - Emerson, Amy
AU  - Emerson A
FAU - Ponte, Linnae
AU  - Ponte L
FAU - Jerome, Lisa
AU  - Jerome L
FAU - Doblin, Rick
AU  - Doblin R
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - J Psychoactive Drugs
JT  - Journal of psychoactive drugs
JID - 8113536
RN  - 0 (Hallucinogens)
SB  - IM
MH  - *Biomedical Research/history/trends
MH  - Clinical Trials as Topic
MH  - *Cooperative Behavior
MH  - *Drug Industry/history/trends
MH  - Forecasting
MH  - Hallucinogens/adverse effects/history/*therapeutic use
MH  - Harm Reduction
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - *Interdisciplinary Communication
MH  - *Organizations, Nonprofit/history/trends
MH  - Patient Safety
MH  - Treatment Outcome
EDAT- 2014/05/17 06:00
MHDA- 2014/06/06 06:00
CRDT- 2014/05/17 06:00
PHST- 2014/05/17 06:00 [entrez]
PHST- 2014/05/17 06:00 [pubmed]
PHST- 2014/06/06 06:00 [medline]
AID - 10.1080/02791072.2014.877321 [doi]
PST - ppublish
SO  - J Psychoactive Drugs. 2014 Jan-Mar;46(1):27-36. doi: 
      10.1080/02791072.2014.877321.